387 related articles for article (PubMed ID: 34554395)
21. Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors.
Sonar P; Shaikh K; Ballav S; Basu S; Harer S
Bioinformation; 2022; 18(10):974-981. PubMed ID: 37654845
[TBL] [Abstract][Full Text] [Related]
22. In-silico Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HT6R Antagonists Targeting Alzheimer's Disease.
V P; A M; N R
Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38204222
[TBL] [Abstract][Full Text] [Related]
23. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
25. Computational analyses of curcuminoid analogs against kinase domain of HER2.
Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
[TBL] [Abstract][Full Text] [Related]
26. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
[TBL] [Abstract][Full Text] [Related]
27. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
Ahmed M; Sadek MM; Abouzid KA; Wang F
J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
[TBL] [Abstract][Full Text] [Related]
28.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
29. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors.
Olivero-Acosta M; Maldonado-Rojas W; Olivero-Verbel J
Molecules; 2017 Feb; 22(2):. PubMed ID: 28218686
[TBL] [Abstract][Full Text] [Related]
30. Anti-Proliferative Potential of Cynaroside and Orientin-In Silico (DYRK2) and In Vitro (U87 and Caco-2) Studies.
Pirvu LC; Pintilie L; Albulescu A; Stefaniu A; Neagu G
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068880
[TBL] [Abstract][Full Text] [Related]
31. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
[TBL] [Abstract][Full Text] [Related]
32. Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer.
Nayarisseri A; Abdalla M; Joshi I; Yadav M; Bhrdwaj A; Chopra I; Khan A; Saxena A; Sharma K; Panicker A; Panwar U; Mendonça Junior FJB; Singh SK
Sci Rep; 2024 Jun; 14(1):13251. PubMed ID: 38858458
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
34. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.
Lintnerová L; García-Caballero M; Gregáň F; Melicherčík M; Quesada AR; Dobiaš J; Lác J; Sališová M; Boháč A
Eur J Med Chem; 2014 Jan; 72():146-59. PubMed ID: 24368209
[TBL] [Abstract][Full Text] [Related]
35. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
Xie J; Zhang X; Meng D; Li Y; Deng P
J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
[TBL] [Abstract][Full Text] [Related]
36. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
37. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
SarathKumar B; Lakshmi BS
J Mol Model; 2019 Aug; 25(9):272. PubMed ID: 31451955
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
Matore BW; Roy PP; Singh J
J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
[TBL] [Abstract][Full Text] [Related]
40. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]